Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Gabapentin for Sleep (100 to 600 mg): Slow-Wave Gains vs. Sleep Apnea Risks
Fishtown Medicine•13 min read
4.96 (124)

Gabapentin for Sleep (100 to 600 mg): Slow-Wave Gains vs. Sleep Apnea Risks

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated November 14, 2026
On This Page
  • How does gabapentin affect sleep architecture (Slow-Wave Sleep vs. Sleep Onset)?
  • What do sleep guidelines and clinical trials show (Gabapentin vs. Placebo and CBT-I)?
  • Does gabapentin worsen sleep apnea (OSA), and what is the FDA 2019 breathing warning?
  • 1. Obstructive Sleep Apnea (OSA) Worsening (Piovezan et al., J Sleep Res 2017)
  • 2. FDA 2019 Respiratory Warning & Opioid Co-Prescribing Mortality (Gomes 2017; Hahn 2022)
  • What are the dose-dependent side effects, weight gain, and withdrawal risks?
  • Kidney Clearance (eGFR Dose Rule) and Rebound Withdrawal
  • How Fishtown Medicine prescribes gabapentin (and when CBT-I comes first)
  • Guidance from the Clinic
  • Actionable Steps
  • Common Questions
  • What dose of gabapentin is used for sleep, and does it help you fall asleep faster?
  • Is 600 mg of gabapentin for sleep a high dose?
  • Is gabapentin safe if you have obstructive sleep apnea (OSA)?
  • Why does gabapentin cause weight gain and swollen ankles?
  • Can you stop gabapentin suddenly if you only take it for sleep?
  • How does Fishtown Medicine prescribe gabapentin?
  • Deep Questions
  • Why are the Rosenberg (2014) and Furey (2014) gabapentin trials not enough to earn an AASM chronic insomnia recommendation?
  • Why does gabapentin increase Stage N3 slow-wave sleep while benzodiazepines suppress it?
  • How do the breathing risks of gabapentin in sleep apnea compare with doxepin or orexin blockers (Messineo 2024; Kishi 2026)?
  • ✦Key Takeaways
  • Related at Fishtown Medicine
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends gabapentin for primary chronic insomnia, and zero placebo-controlled RCTs have tested it in diagnosed chronic insomnia disorder (very low certainty overall). While off-label bedtime gabapentin (100 to 600 mg) increases deep slow-wave sleep (Stage N3) and reduces wake after sleep onset (WASO by -35 to -62.5 minutes) in artificial 5-hour phase-advance models of transient sleep disruption (Rosenberg 2014; Furey 2014), it does not shorten sleep-onset latency (SOL) and carries significant harms: a +84% increase in the apnea-hypopnea index (AHI 22.4 vs 12.2/hr) and +91% jump in oxygen desaturation index after a single 300 mg bedtime dose in older men (Piovezan 2017, NNH 4), an FDA 2019 respiratory depression warning (opioid co-prescribing death aOR 1.49 to 1.58, Gomes 2017), dose-related dizziness (NNH 8), peripheral edema (NNH 20), weight gain, and a withdrawal syndrome. Fishtown Medicine reserves gabapentin for insomnia driven by restless legs syndrome, neuropathic pain, or vasomotor night waking, in Pennsylvania and New Jersey only with an in-person visit every six months.

TL;DR: Gabapentin (100 to 600 mg off-label at bedtime; up to 1,800 mg/day in pain/recovery trials) is one of the few drugs that increases deep slow-wave sleep (Stage N3), which is why it gets prescribed so often for sleep. Yet the PICO evidence shows why it is never a casual sleeping pill:

  1. Zero chronic-insomnia RCTs & zero guideline endorsement (AASM, ACP, VA/DoD): No sleep guideline recommends gabapentin for primary chronic insomnia (very low certainty). Zero double-blind, placebo-controlled RCTs have tested gabapentin in adults with chronic insomnia disorder. The two largest sleep trials (Rosenberg 2014, n = 377; Furey 2014, n = 256) put occasional poor sleepers to bed 5 hours early (phase-advance model). That cut night waking (WASO) by 35 to 62.5 minutes with zero effect on time to fall asleep (SOL). For primary chronic insomnia, multicomponent CBT-I is the strong first-line recommendation (SOL -19 min, WASO -26 min, lasting at 12 months).
  2. The sleep apnea (+84% AHI) and FDA 2019 breathing warnings (Piovezan 2017; Gomes 2017): In a double-blind crossover trial (Piovezan et al., J Sleep Res 2017), a single 300 mg bedtime dose of gabapentin raised the apnea-hypopnea index (AHI) by +84% (22.4 vs 12.2 events/hr, NNH = 4) and oxygen drops (ODI) by +91% during NREM sleep. The FDA (2019) and 2023 AGS Beers Criteria warn against serious breathing slowdowns when gabapentin is combined with opioids (49% to 58% higher odds of opioid-related death, Gomes et al., PLoS Med 2017), other sedatives, COPD, or older age.
  3. When gabapentin fits (RLS, nerve pain, hot flashes) and how we prescribe it: Gabapentin makes sense when insomnia shares a root cause it directly treats, such as restless legs syndrome (RLS), nerve pain, or menopausal night sweats. Because of its breathing, weight-gain (>= 5% body weight in 57% at 12 months), and rebound withdrawal risks, Fishtown Medicine prescribes gabapentin in Pennsylvania and New Jersey only, with an in-person visit every 6 months, kidney (eGFR) dose checks, and sleep apnea screening.

Gabapentin was treated for two decades as a harmless, unscheduled alternative to sleeping pills. That reputation grew by comparing it with benzodiazepines instead of testing it in chronic insomnia. When you read the sleep-lab (PSG) trials and safety studies, a clear boundary emerges.

Three-column clinical diagram of Gabapentin for Insomnia: Column 1 shows Sleep Architecture and Trial Limits (Alpha-2-delta calcium channel binding increases Slow-Wave Sleep [Stage N3 +12 to +20%, Foldvary-Schaefer 2002, Yeh 2021] and cuts WASO by -35 to -62.5 min in 5-hour phase-advance transient models [Rosenberg 2014 n=377, Furey 2014 n=256], with ZERO placebo-controlled RCTs in diagnosed chronic insomnia disorder, NO improvement in sleep-onset latency [SOL], and ungraded status in AASM 2017, ACP 2016, and VA/DoD 2025); Column 2 details Sleep Apnea [OSA] and Respiratory Risks (Piovezan 2017 crossover RCT showing 300 mg at bedtime raised AHI +84% from 12.2 to 22.4 events/hr and ODI +91% from 10.8 to 20.6/hr [NNH = 4]; FDA 2019 respiratory depression warning and Gomes 2017 opioid-related death aOR 1.49-1.58; Cochrane side effects including dizziness NNH 8, somnolence NNH 11, peripheral edema NNH 20, and >=5% weight gain in 57% at 12 months); Column 3 shows When It Fits and Safer First-Line Care (Use gabapentin ONLY when insomnia has a concordant driver like Restless Legs Syndrome, neuropathic pain, or menopausal vasomotor night waking after OSA screening, eGFR dose check, and 6-month in-person PA/NJ follow-up; Use CBT-I first-line for primary chronic insomnia).
How gabapentin alters slow-wave sleep architecture, why a single 300 mg dose raised the apnea-hypopnea index by 84% in crossover testing, and when a comorbid driver justifies its use.

How does gabapentin affect sleep architecture (Slow-Wave Sleep vs. Sleep Onset)?

Gabapentin binds the alpha-2-delta (\alpha_2\delta) subunit of voltage-gated calcium channels, quieting excitatory nerve release and increasing deep slow-wave sleep (Stage N3) and sleep maintenance (WASO), without shortening the time it takes to fall asleep (SOL).123

Despite its name, gabapentin does not bind GABA-A or GABA-B receptors:

  • Why deep sleep rises (Foldvary-Schaefer et al., Epilepsia 2002; Yeh et al., Sleep Med 2021): Benzodiazepines and Z-drugs act on GABA-A receptors, which speeds up sleep onset while flattening the slow brain waves that generate restorative Stage N3 slow-wave sleep (SWS). By calming calcium entry at \alpha_2\delta channels, gabapentin (1,500 to 1,800 mg/day in healthy adults, Foldvary-Schaefer 2002) and related drugs increase SWS across 18 sleep-lab RCTs (Yeh et al., 2021), fibromyalgia (Roth 2012), and restless legs syndrome (Winkelman 2011, N3 +12.1 min).4567
  • The clinical gap: Whether drug-induced gains in SWS improve daytime focus or health outcomes in primary chronic insomnia has never been proven in a trial.12

What do sleep guidelines and clinical trials show (Gabapentin vs. Placebo and CBT-I)?

No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends or grades gabapentin for chronic insomnia (very low certainty). Zero placebo-controlled RCTs have tested gabapentin in chronic insomnia disorder, and a 2022 review (Hong et al., Mol Psychiatry) concluded gabapentin should only be used when a separate condition justifies it.189101112

Trial or GuidelineDesign & Population (n)Gabapentin DoseSleep Maintenance (WASO), Onset (SOL), & Total Sleep (TST)Key Clinical Limit
AASM 2017/2021, ACP 2016, & VA/DoD 2019/2025 GuidelinesClinical practice guidelinesNot graded (AASM excluded Lo 2010 due to open-label design, n = 18, no placebo)813No recommendation for gabapentin in chronic insomnia; STRONG recommendation for CBT-I (49 RCTs, moderate certainty).891011Lack of a guideline grade reflects missing primary insomnia RCTs instead of approval.811
Single-Night 5-Hr Phase Advance (Rosenberg et al., JCSM 2014)Double-blind, 3-arm PSG RCT (n = 377 occasional poor sleepers put to bed 5 hrs early)Single dose: 250 mg or 500 mg vs placeboWASO: 135.7 min (placebo) vs 100.7 min (250 mg, -35.0 min / -26%) vs 73.2 min (500 mg, -62.5 min / -46%); TST +45 & +67 min; SWS 12.6% -> 15.4% -> 17.0%; SOL unchanged.2Artificial jet-lag (5-hr phase advance) model in healthy adults; did not enroll chronic insomnia patients.2
28-Day 5-Hr Phase Advance (Furey et al., JCSM 2014)Double-blind PSG RCT (n = 256 occasional poor sleepers)250 mg or 500 mg nightly for 28 daysWASO Day 1: 107.0 vs 149.1 min (-42.1 min / -28%); Day 28: 113.6 vs 152.3 min (-38.7 min / -25%); TST +63.7 & +46.2 min; no tolerance at Day 28.3Longest sleep RCT is only 28 days and did not enroll chronic insomnia patients.3
Alcohol Dependence + Insomnia (Brower et al., 2008; Mason et al., JAMA Intern Med 2014; Hong et al., Mol Psychiatry 2022)Double-blind RCTs (n = 21 for 6 wks; n = 150 for 12 wks; pooled n = 171 in Hong 2022)Up to 1,500 to 1,800 mg at bedtimeBrower 2008 showed zero PSG or diary sleep gain vs placebo; Mason 2014 (1,800 mg) improved PSQI by -1.5 points; pooled review (Hong 2022, n = 171) showed no sleep scale benefit.121415Hong et al. (2022) judged insomnia evidence inconclusive and advised against use without strong comorbidity justification.12
Comorbid Medical Illness & Hot Flashes (Liu et al., Front Neurol 2017; Pinkerton 2014; Yurcheshen 2009)Meta-analysis & hot-flash RCTs300 to 1,800 mg/dayImproved secondary sleep scores in nerve pain, RLS, and menopausal night waking.161718Sleep gains follow from fewer hot flashes, less pain, or calmer legs, with high dropout rates at ~1,800 mg/day.1617
First-Line Benchmark: Multicomponent CBT-I (Trauer et al., Ann Intern Med 2015; Gao 2022; Morin & Buysse, NEJM 2024)20 RCT meta-analysis (n = 1,162) & 61 RCT network (n = 11,571) in chronic insomnia4 to 8 structured sessionsSOL -19.0 min, WASO -26.0 min, sleep efficiency +9.9%; 60% to 70% response and 40% to 45% remission lasting at 12 months.192021Across 23 RCTs vs sleep pills (Zhang 2022; Perlis 2022), only CBT-I keeps working after stopping treatment.2223

Does gabapentin worsen sleep apnea (OSA), and what is the FDA 2019 breathing warning?

Yes. In a randomized, double-blind crossover trial (Piovezan et al., J Sleep Res 2017), a single 300 mg bedtime dose of gabapentin raised the apnea-hypopnea index (AHI) by +84% (22.4 vs 12.2 events/hr, NNH = 4) and the oxygen desaturation index (ODI) by +91%. In December 2019, the FDA issued a class-wide respiratory warning for gabapentin and pregabalin.242526

1. Obstructive Sleep Apnea (OSA) Worsening (Piovezan et al., J Sleep Res 2017)

Many adults with broken sleep have undiagnosed obstructive sleep apnea:

  • The +84% AHI crossover signal (Piovezan et al., 2017, n = 8 non-obese older men without known OSA): After a single 300 mg bedtime dose of gabapentin, sleep-lab testing showed the apnea-hypopnea index (AHI) jumped from 12.2 +/- 4.3 on placebo to 22.4 +/- 6.1 events/hour (+10.2 events/hr or +84% jump; d = 0.67; NNH = 4 for pushing AHI into the moderate-to-severe range).24
  • +91% more oxygen drops: The oxygen desaturation index (ODI) rose from 10.8 to 20.6 drops/hour (+91%), concentrated during NREM sleep and back (supine) sleeping, likely by relaxing upper-airway muscle tone.24 No RCT has yet tested gabapentin in patients with established severe OSA, and gabapentin weight gain can worsen OSA further over time (Rehim et al., Epilepsia 2026).2427
  • Contrast with targeted sleep drugs (Messineo AJRCCM 2024; Kishi 2026; Mason Cochrane 2015; Carter 2018): Across reviews of 32 RCTs in OSA, dual orexin blockers (lemborexant, daridorexant) and standard-dose zolpidem / zopiclone did not raise AHI (AHI -1.4 events/hr, Messineo 2024). That makes gabapentin's +84% AHI jump a distinct airway concern.28293031

2. FDA 2019 Respiratory Warning & Opioid Co-Prescribing Mortality (Gomes 2017; Hahn 2022)

  • FDA & CDC safety data (Kuehn JAMA 2022; Fernández-Liz 2022): In December 2019, the FDA mandated warnings for serious breathing problems with gabapentin (49 initial reports, 12 deaths, 92% having at least one risk factor: opioids, other sedatives, COPD, or older age).2526 By 2019-2020, CDC data found gabapentin in ~10% of US overdose deaths (5,687 of 58,362), with ~90% also involving opioids.2532
  • Mortality odds (Gomes et al., PLoS Med 2017; Hahn et al., Front Pharmacol 2022; Hart et al., JAGS 2025): In a nested case-control study (Gomes et al., 2017, 1,256 cases and 4,619 controls), combining gabapentin with an opioid raised the odds of opioid-related death by 49% (aOR 1.49, 95% CI 1.18 to 1.88), rising to 58% (aOR 1.58) at gabapentin >= 1,800 mg/day.33 Across observational studies (Hahn et al., 2022), combination therapy carried a breathing slowdown OR of 1.71 (95% CI 1.31 to 2.24) and death OR of 2.76.34 In Medicare patients (Hart 2025), gabapentin + opioids doubled all-cause death (HR 2.03) compared with duloxetine + opioids.35 The 2023 AGS Beers Criteria issue a strong recommendation to avoid combining gabapentinoids with opioids.36 (Fishtown Medicine does not prescribe opioids for any condition, and we never add gabapentin to an outside opioid or sedative regimen.)

What are the dose-dependent side effects, weight gain, and withdrawal risks?

Across FDA trials and Cochrane reviews (Wiffen et al., 2017; Meaadi et al., 2023), gabapentin causes dose-related dizziness (NNH 8), drowsiness (NNH 11), unsteady walking (NNH 8.5), ankle swelling (NNH 20), and weight gain (>= 5% body weight in 57% of adults at 12 months), plus rebound insomnia if stopped suddenly.37383940

Side Effect / Safety DomainTrial Rate (Gabapentin vs. Placebo)Relative Risk (RR) & Number Needed to Harm (NNH)Clinical Context & Care
Dizziness (FDA Label; Cochrane 2017)28% vs 8% (FDA trials); 19% vs 6.6% (Cochrane >= 1,200 mg/day)NNH = 83739Top cause of falls in older adults; start low (100 mg) and check kidney function (eGFR).37
Somnolence / Next-Day Drowsiness (FDA Label; Cochrane 2017)21% vs 5% (FDA trials); 14% vs 5.2% (Cochrane)RR 2.8 (NNH = 11)3739Compounds with alcohol, antihistamines, Z-drugs, or benzodiazepines.3739
Ataxia / Unsteady Walking (FDA Label; Cochrane 2017)3% vs 0% (FDA label); gait trouble in CochraneNNH = 8.53739Raises nighttime bathroom fall risk.39
Peripheral Edema / Ankle Swelling (FDA Label; Cochrane 2017)8% vs 2% (FDA trials); 6.7% vs 1.7% (Cochrane)RR 4.1 (NNH = 20)3739Calcium-channel vessel dilation in the legs; clears when gabapentin is tapered off.3739
Weight Gain (Meaadi 2023; Medici 2016; Kaye 2025)Meta-analytic NNH = 28 in short RCTs; 57% gained >= 5% body weight and 23% gained >= 10% over 12 months (n = 44 cohort)NNH = 28 (short-term); 57% (>= 5% wt gain at 1 yr)404142Dose-dependent appetite and fluid shift that can worsen metabolic health and OSA.4142
Stopping Due to Side Effects (FDA Label; Cochrane)16% vs 9% (FDA trials); any side effect 63% vs 49% (Cochrane)Any AE NNH = 7373839High drop-out rate at doses >= 1,200 to 1,800 mg/day (Liu 2017).1639

Kidney Clearance (eGFR Dose Rule) and Rebound Withdrawal

  1. 100% Kidney Excretion (FDA Label): Gabapentin is not broken down by the liver and leaves unchanged in urine.3738 Lower kidney function (check your Cystatin C and eGFR) causes gabapentin to build up, raising drowsiness, unsteadiness, and breathing risk unless the dose is lowered when eGFR < 60 mL/min/1.73m².37
  2. Sudden Stopping & Rebound Insomnia: Stopping gabapentin suddenly after months of nightly use can trigger rebound insomnia, anxiety, sweating, nausea, tremor, rapid heart rate, and rarely seizures.3842 Because the first 3 to 5 nights off gabapentin feel worse than baseline, many people think they cannot sleep without it. Tapering over 1 to 2+ weeks prevents withdrawal.

Evidence-Based Treatment

Dr. Ash reviews the research - and applies it to your specific biology.

Book a Consultation

How Fishtown Medicine prescribes gabapentin (and when CBT-I comes first)

At Fishtown Medicine, gabapentin is placed in our tethered medication group alongside scheduled drugs:

  • Prescribed in Pennsylvania and New Jersey only, with an in-person visit every 6 months: Several states classify gabapentin as a Schedule V controlled substance or require state monitoring (PDMP) due to misuse risk (Kuehn JAMA 2022). We require a written clinical reason, an eGFR check, sleep apnea screening, and a 6-month in-person visit in PA or NJ.25
  • When gabapentin is the right tool: When insomnia is driven by restless legs syndrome (RLS), nerve pain that wakes you at night, or menopausal night sweats (Pinkerton 2014), a low bedtime dose (100 to 300 mg, up to 600 mg) can treat two problems with one drug.1717
  • When CBT-I comes first: For primary chronic insomnia without nerve pain or RLS, multicomponent CBT-I (Scott JAMA Intern Med 2025; Bai 2024; Xu 2024) is our first-line care.91943

Guidance from the Clinic

Dr. Ash
"Gabapentin got treated for years as the harmless sleep option, and that was never the whole story. Yes, it increases Stage N3 slow-wave sleep. If restless legs, nerve pain, or night sweats wake you up at 2 a.m., 100 to 300 mg at bedtime can solve two problems at once. However, zero trials have tested it in primary chronic insomnia disorder. A single 300 mg dose raised the sleep apnea index by 84% in crossover testing, and over a year more than half of patients on full doses gain at least 5% of their body weight. Before we continue or start gabapentin, we screen for sleep apnea, check your kidney function, confirm what problem it is treating, and pair it with a lasting sleep plan."

Actionable Steps

Safety checklist if you take or are considering gabapentin for sleep:

  1. Name the Root Driver (RLS, Nerve Pain, or Hot Flashes vs. Primary Insomnia): If you have chronic insomnia without restless legs, nerve pain, or night sweats, start with multicomponent CBT-I (SOL -19 min, WASO -26 min), which has 49+ RCTs and lasting 12-month remission (Edinger 2021; Trauer 2015).
  2. Screen for Obstructive Sleep Apnea First (Piovezan 2017 Rule): A single 300 mg bedtime dose raised AHI by +84% and oxygen drops by +91% (NNH = 4). Rule out or treat sleep apnea before using gabapentin at night, particularly if you snore or wake unrefreshed.
  3. Never Combine Gabapentin with Opioids or Multiple Sedatives (FDA 2019 & Beers 2023): Co-prescribing with opioids raises opioid-related death odds by 49% to 58% (Gomes 2017) and breathing slowdown odds by 71% (Hahn 2022).
  4. Check Kidney Function (eGFR) and Track Weight & Ankle Swelling: Gabapentin is 100% cleared by the kidneys and carries a NNH = 20 for ankle swelling and 57% rate of >= 5% weight gain at 12 months (Meaadi 2023; Medici 2016). Use the lowest effective bedtime dose (100 to 300 mg).
  5. Taper Gradually (Never Stop Cold Turkey): If you and your doctor decide to stop nightly gabapentin, taper down over 1 to 2+ weeks to avoid rebound insomnia and withdrawal. Start an intake with Dr. Ash to review your sleep plan.
✦

Key Takeaways

  1. No major sleep guideline (AASM 2017/2021, ACP 2016, VA/DoD 2019/2025) recommends gabapentin for chronic insomnia (very low certainty), and zero placebo-controlled RCTs exist in chronic insomnia disorder.18101112
  2. Gabapentin increases deep slow-wave sleep (Stage N3) and cuts WASO (-35 to -62.5 min) in 5-hour phase-advance models (Rosenberg 2014; Furey 2014), without helping you fall asleep faster (SOL).234
  3. A single 300 mg bedtime dose raised the apnea-hypopnea index (AHI) by +84% and oxygen drops (ODI) by +91% (NNH = 4, Piovezan 2017), and the FDA 2019 warning highlights serious breathing risk with opioids (death aOR 1.49 to 1.58, Gomes 2017), sedatives, COPD, or older age.24253336
  4. Expect dose-related dizziness (NNH 8), drowsiness (NNH 11), ankle swelling (NNH 20), and weight gain (>= 5% in 57% at 12 months), and always taper gradually to avoid rebound insomnia.373941
  5. Use CBT-I first-line for primary chronic insomnia, and save gabapentin for insomnia driven by RLS, nerve pain, or night sweats (PA and NJ only at Fishtown Medicine, with 6-month in-person follow-up).1919

Related at Fishtown Medicine

  • CBT-I for insomnia
  • Hydroxyzine for sleep
  • Is it insomnia or sleep apnea?
  • Z-drugs for insomnia
  • Doxepin for sleep
  • Insomnia

Scientific References

  1. Krystal AD, Prather AA, Ashbrook LH. "The assessment and management of insomnia: an update." World Psychiatry. 2019;18(3):337-352. DOI
  2. Rosenberg RP, Hull SG, Lankford DA, et al. "A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study of Gabapentin in Transient Insomnia Induced by Sleep Phase Advance." Journal of Clinical Sleep Medicine. 2014;10(10):1093-1100. PubMed
  3. Furey SA, Hull SG, Leibowitz MT, Jayawardena S, Roth T. "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-Day, Polysomnographic Study of Gabapentin in Transient Insomnia Induced by Sleep Phase Advance." Journal of Clinical Sleep Medicine. 2014;10(10):1101-1109. PubMed
  4. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. "Gabapentin Increases Slow-Wave Sleep in Normal Adults." Epilepsia. 2002;43(12):1493-1497. DOI
  5. Yeh WC, Lu SR, Wu MN, et al. "The Impact of Antiseizure Medications on Polysomnographic Parameters: A Systematic Review and Meta-Analysis." Sleep Medicine. 2021;81:319-328. PubMed
  6. Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. "Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: A randomized, placebo-controlled, 2-way crossover polysomnography study." Arthritis Care & Research. 2012;64(4):597-606. DOI
  7. Winkelman JW, Bogan RK, Schmidt MH, et al. "Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome." Movement Disorders. 2011;26(11):2065-2072. DOI
  8. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2017;13(2):307-349. PMC
  9. Edinger JD, Arnedt JT, Bertisch SM, et al. "Behavioral and Psychological Treatments for Chronic Insomnia Disorder in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2021;17(2):255-262. PMC
  10. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. "Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians." Annals of Internal Medicine. 2016;165(2):125-133. DOI
  11. Sharafkhaneh A, Thomas A, Ulmer C, et al. "VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea (Insomnia/OSA)." Department of Veterans Affairs & Department of Defense. 2025. Guideline PDF
  12. Hong JSW, Atkinson LZ, Al-Juffali N, et al. "Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale." Molecular Psychiatry. 2022;27(3):1339-1349. DOI
  13. Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS. "Treatment Effects of Gabapentin for Primary Insomnia." Clinical Neuropharmacology. 2010;33(2):84-90. PubMed
  14. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. "A Randomized Double-Blind Pilot Trial of Gabapentin Versus Placebo to Treat Alcohol Dependence and Comorbid Insomnia." Alcoholism: Clinical and Experimental Research. 2008;32(8):1429-1438. PubMed
  15. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. "Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial." JAMA Internal Medicine. 2014;174(1):70-77. DOI
  16. Liu GJ, Karim MR, Xu LL, Wang YH,yda M. "Efficacy and Tolerability of Gabapentin in Adults With Sleep Disturbance in Medical Illness: A Systematic Review and Meta-Analysis." Frontiers in Neurology. 2017;8:316. PubMed
  17. Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M. "Phase 3 Randomized Controlled Study of Gastroretentive Gabapentin for the Treatment of Moderate-to-Severe Hot Flashes in Menopause." Menopause. 2014;21(6):567-573. PubMed
  18. Yurcheshen ME, Guttuso T, McDermott M, Holloway RG, Perlis M. "Effects of Gabapentin on Sleep in Menopausal Women with Hot Flashes as Measured by a Pittsburgh Sleep Quality Index Factor Scoring Model." Journal of Women's Health. 2009;18(9):1355-1360. DOI
  19. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. "Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-Analysis." Annals of Internal Medicine. 2015;163(3):191-204. PubMed
  20. Gao Y, Ge L, Liu M, et al. "Comparative Efficacy and Acceptability of Cognitive Behavioral Therapy Delivery Formats for Insomnia in Adults: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;64:101648. PubMed
  21. Morin CM, Buysse DJ. "Management of Insomnia." The New England Journal of Medicine. 2024;391(3):247-258. DOI
  22. Zhang Y, Ren R, Yang L, et al. "Comparative Efficacy and Acceptability of Psychotherapies, Pharmacotherapies, and Their Combination for the Treatment of Adult Insomnia: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;65:101687. PubMed
  23. Perlis ML, Posner D, Riemann D, Bastien CH, Teichtenberg L, Thase M. "Insomnia." The Lancet. 2022;400(10357):1047-1060. PubMed
  24. Piovezan RD, Kase C, Moizinho R, Tufik S, Poyares D. "Gabapentin Acutely Increases the Apnea-Hypopnea Index in Older Men: Data From a Randomized, Double-Blind, Placebo-Controlled Study." Journal of Sleep Research. 2017;26(2):166-170. PubMed
  25. Kuehn BM. "Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices." JAMA. 2022;328(13):1283-1285. DOI
  26. Fernández-Liz E, Barceló-Colomer ME, Gómez-Ganda L, et al. "Prevalence of Gabapentinoids and Central Nervous System Depressant Drugs, and Their Association with Risk Factors for Respiratory Depression in Primary Care Patients." Clinical Drug Investigation. 2022;42(5):417-426. DOI
  27. Rehim ED, Vendrame M, Devinsky O. "Obstructive sleep apnea in people with epilepsy: Modifying risk." Epilepsia. 2026. DOI
  28. Mason M, Cates CJ, Smith I. "Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea." Cochrane Database of Systematic Reviews. 2015;(7):CD011090. DOI
  29. Messineo L, Sands SA, Labarca G. "Hypnotics on Obstructive Sleep Apnea Severity and Endotypes: A Systematic Review and Meta-Analysis." American Journal of Respiratory and Critical Care Medicine. 2024;210(9):1135-1148. PubMed
  30. Kishi T, Ikuta T, Sakuma K, et al. "Comparative Effects of Hypnotic Agents on Sleep Architecture and Respiratory Outcomes in Obstructive Sleep Apnea: A Systematic Review and Network Meta-Analysis." Psychiatry and Clinical Neurosciences. 2026. PubMed
  31. Carter SG, Carberry JC, Cho G, et al. "Effect of 1 month of Zopiclone on Obstructive Sleep Apnoea Severity and Symptoms: A Randomised Controlled Trial." European Respiratory Journal. 2018;52(1):1800149. PubMed
  32. Kuehn BM. "Gabapentin Increasingly Implicated in Overdose Deaths." JAMA. 2022;327(24):2387. DOI
  33. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. "Gabapentin, Opioids, and the Risk of Opioid-Related Death: A Population-Based Nested Case-Control Study." PLoS Medicine. 2017;14(10):e1002396. PubMed
  34. Hahn J, Jo Y, Yoo SH, Shin J, Yu YM, Ah YM. "Risk of Major Adverse Events Associated With Gabapentinoid and Opioid Combination Therapy: A Systematic Review and Meta-Analysis." Frontiers in Pharmacology. 2022;13:1009950. PubMed
  35. Hart LA, Vo S, Hanlon JT, Schmader KE, Gray SL. "Medication Use Quality and Safety in Older Adults: 2023 Update." Journal of the American Geriatrics Society. 2025;73(2):365-375. DOI
  36. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society. 2023;71(7):2052-2081. DOI
  37. Food and Drug Administration. "Neurontin (Gabapentin) Prescribing Information." Updated July 2026. DailyMed
  38. Food and Drug Administration. "Gabapentin Capsules Prescribing Information." Updated May 2025. DailyMed
  39. Wiffen PJ, Derry S, Bell RF, et al. "Gabapentin for chronic neuropathic pain in adults." Cochrane Database of Systematic Reviews. 2017;6(6):CD007938. DOI
  40. Meaadi J, Obara I, Eldabe S, Nazar H. "The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials." International Journal of Clinical Pharmacy. 2023;45(3):556-565. DOI
  41. Medici V, McClave SA, Miller KR. "Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity." Current Gastroenterology Reports. 2016;18(1):2. DOI
  42. Kaye AD, Cassagne G, Abbott BM, et al. "Emerging Clinical Roles of Gabapentin and Adverse Effects, Including Weight Gain, Obesity, Depression, Suicidal Thoughts and Increased Risk of Opioid-Related Overdose and Respiratory Depression: A Narrative Review." Current Pain and Headache Reports. 2025;29(1):45. DOI
  43. Scott AJ, Correa AB, Bisby MA, et al. "Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease: A Systematic Review and Meta-Analysis." JAMA Internal Medicine. 2025. DOI
Medical Disclaimer: This resource provides clinical context for educational purposes and is not medical advice. In Precision Medicine, the right sleep plan must be matched to your unique history, kidney function, sleep apnea screening, and goals. Never stop gabapentin abruptly without medical supervision. Consult Dr. Ash or your own physician before starting, changing, or tapering any prescription medication.
Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Treatments

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Off-label sleep dosing starts at 100 to 300 mg (up to 600 mg) taken 1 to 2 hours before bed, lowered if kidney function (eGFR) is reduced.<sup>37</sup> In placebo-controlled sleep-lab trials (Rosenberg et al., JCSM 2014, n = 377; Furey et al., JCSM 2014, n = 256), gabapentin (250 to 500 mg) cut wake after sleep onset (WASO) by 35 to 62.5 minutes and increased Stage N3 slow-wave sleep, with no effect on time to fall asleep (SOL).<sup>2</sup><sup>3</sup>
For sleep alone, 600 mg is at the top of the typical off-label bedtime range (100 to 600 mg), whereas 600 mg taken at 5:00 PM is the standard FDA-approved dose of extended-release gabapentin enacarbil for restless legs syndrome (Winkelman et al., 2011).<sup>7</sup><sup>37</sup> In sleep-lab phase-advance trials (Rosenberg 2014; Furey 2014), 500 mg cut night waking (WASO) by 62.5 minutes vs 35.0 minutes at 250 mg.<sup>2</sup><sup>3</sup> However, moving from 100-300 mg up to 600 mg increases next-day drowsiness (NNH 11) and dizziness (NNH 8), requires full kidney clearance (eGFR >= 60 mL/min/1.73m²), and builds on the +84% sleep apnea (AHI) jump already seen at 300 mg (Piovezan 2017).<sup>24</sup><sup>37</sup><sup>39</sup>
Use caution. In a randomized, double-blind crossover trial (Piovezan et al., J Sleep Res 2017), a single 300 mg bedtime dose of gabapentin raised the apnea-hypopnea index (AHI) by +84% (from 12.2 to 22.4 events/hour, NNH = 4) and raised the oxygen desaturation index (ODI) by +91% (from 10.8 to 20.6/hour) during NREM and back sleeping.<sup>24</sup> Paired with the FDA 2019 breathing warning, untreated sleep apnea should be screened for and treated before using gabapentin.<sup>24</sup><sup>25</sup>
Gabapentin blocks \alpha_2\delta calcium channels, which can dilate leg blood vessels (causing ankle and foot swelling in 6.7% to 8% of patients vs 1.7% to 2% on placebo; RR 4.1, NNH = 20) and raise appetite.<sup>37</sup><sup>39</sup> Across reviews (Meaadi et al., 2023, NNH = 28) and 12-month follow-up (Medici et al., 2016), 57% of adults taking chronic gabapentin gained >= 5% of their body weight and 23% gained >= 10%.<sup>40</sup><sup>41</sup><sup>42</sup>
No. Stopping gabapentin suddenly after nightly use can trigger withdrawal marked by rebound insomnia, anxiety, sweating, nausea, tremor, and rarely seizures.<sup>38</sup><sup>42</sup> Because rebound insomnia peaks in the first few nights after stopping, people often mistake withdrawal for proof that they still need the pill. Always taper over 1 to 2+ weeks with your prescriber.
Because gabapentin is tracked in state monitoring programs (PDMPs) and carries breathing and withdrawal risks, Fishtown Medicine treats it as a tethered medication. Dr. Ash prescribes it in Pennsylvania and New Jersey only, requires an in-person visit every 6 months, checks kidney function (eGFR) and sleep apnea risk, and saves it for insomnia driven by restless legs syndrome, neuropathic pain, or vasomotor night sweats.

Deep-Dive Questions

Neither trial enrolled patients with chronic insomnia disorder.<sup>1</sup><sup>2</sup><sup>3</sup> Instead, both Rosenberg et al. (JCSM 2014, n = 377) and Furey et al. (JCSM 2014, n = 256) used an artificial 5-hour sleep phase-advance model (putting healthy adults with occasional poor sleep to bed 5 hours early) to mimic jet-lag sleep maintenance trouble.<sup>2</sup><sup>3</sup> Meanwhile, the only primary insomnia study (Lo et al., Clin Neuropharmacol 2010, n = 18) had no placebo group and was excluded by AASM 2017 (Sateia et al.).<sup>8</sup><sup>13</sup> Pooled RCTs in alcohol dependence (Brower 2008; Mason 2014; Hong et al., Mol Psychiatry 2022, n = 171) showed no significant sleep-scale gain over placebo.<sup>12</sup><sup>14</sup><sup>15</sup>
Deep slow-wave oscillations (0.5 to 4 Hz delta waves in Stage N3) depend on synchronized firing between the thalamus and cortex. Benzodiazepines and Z-drugs activate GABA-A receptors across the cortex, which speeds up sleep onset (SOL) while flattening delta waves and cutting Stage N3 sleep. Gabapentin binds the \alpha_2\delta-1 subunit of presynaptic calcium channels, quieting excess glutamate and norepinephrine release in arousal pathways without clamping GABA-A receptors (Foldvary-Schaefer 2002; Yeh et al., Sleep Med 2021).<sup>4</sup><sup>5</sup>
In Piovezan et al. (J Sleep Res 2017), 300 mg of gabapentin raised AHI by +10.2 events/hour (+84%) and ODI by +91% (NNH = 4).<sup>24</sup> By contrast, meta-analyses of approved sleep medicines in patients with OSA (Messineo et al., AJRCCM 2024; Kishi et al., Psychiatry Clin Neurosci 2026, 32 RCTs; Carter et al., Eur Respir J 2018) show that dual orexin blockers (lemborexant, daridorexant) and standard-dose Z-drugs do not worsen AHI (mean change -1.4 events/hr, 95% CI -3.5 to +0.7) or overnight oxygen levels.<sup>28</sup><sup>29</sup><sup>30</sup><sup>31</sup>

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

CBT-I for Chronic Insomnia: Why Sleep Restriction Outlasts Sleeping Pills and When Orexin Blockers Help

CBT-I for Chronic Insomnia: Why Sleep Restriction Outlasts Sleeping Pills and When Orexin Blockers Help

Both the ACP and AASM recommend CBT-I ahead of any sleeping pill because its gains hold at 6 and 12 months. How sleep restriction and stimulus control work, why orexin blockers (DORAs) beat Z-drugs and trazodone when a bridge is needed, and why 0.5 mg timed melatonin beats 5-10 mg bedtime gummies.

Read Deep Dive
Doxepin for Sleep (3 to 6 mg vs. 10 to 150 mg): Trials, H1 Selectivity, and Antihistamine Comparison

Doxepin for Sleep (3 to 6 mg vs. 10 to 150 mg): Trials, H1 Selectivity, and Antihistamine Comparison

Clinical guide to ultra-low-dose doxepin (3 to 6 mg) vs. 10 to 150 mg tricyclic doses, hydroxyzine, and Benadryl: human-brain H1 binding (Kd 0.24 nM), AASM sleep-maintenance trials (WASO -22 to -23 min through Night 85), 2023 Beers Criteria<=6 mg rule, and anticholinergic dementia cohorts.

Read Deep Dive
Hydroxyzine for Sleep: Dose, Tolerance, Driving Risk, and QTc

Hydroxyzine for Sleep: Dose, Tolerance, Driving Risk, and QTc

PICO review of hydroxyzine (25 to 100 mg) vs placebo and CBT-I for adult insomnia: why no guideline recommends it, 4-day H1 sedation tolerance, 20-hour half-life driving impairment (0.05 to 0.08% BAC equivalent), QTc/torsades warnings, and Beers Criteria anticholinergic risk.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

Share what is weighing on you and what support has or has not helped. Dr. Ash reads every intake personally.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs